Ignite Creation Date:
2025-12-24 @ 1:30 PM
Ignite Modification Date:
2026-01-26 @ 7:26 PM
Study NCT ID:
NCT07287995
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Locally Advanced or Metastatic Malignant Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Safety | View |
| None | Tolerability | View |
| None | Pembrolizumab | View |
| None | Enfortumab Vedotin | View |
| None | Carboplatin | View |
| None | Non-small cell lung cancer | View |
| None | Gastroesophageal junction cancer | View |
| None | Breast cancer | View |
| None | Pharmacokinetics | View |
| None | Urothelial carcinoma | View |
| None | ASP2998 | View |